The University of Chicago Header Logo

Connection

Hedy Kindler to Pleural Neoplasms

Back to Details
This is a "connection" page, showing publications Hedy Kindler has written about Pleural Neoplasms.
Hedy Kindler
Connection Strength
10.816
Pleural Neoplasms
  1. Understanding the new therapeutic options for mesothelioma. Lancet Oncol. 2021 10; 22(10):1353-1355.
    View in: PubMed
    Score: 0.703
  2. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 11; 21(6):553-561.e1.
    View in: PubMed
    Score: 0.648
  3. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018 04; 14(4):256-264.
    View in: PubMed
    Score: 0.552
  4. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 05 01; 36(13):1343-1373.
    View in: PubMed
    Score: 0.547
  5. MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013 May; 8(5):e49-50.
    View in: PubMed
    Score: 0.394
  6. Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1623-4.
    View in: PubMed
    Score: 0.381
  7. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012 Sep; 77(3):567-71.
    View in: PubMed
    Score: 0.372
  8. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
    View in: PubMed
    Score: 0.370
  9. Surgery for mesothelioma? The debate continues. Lancet Oncol. 2011 Aug; 12(8):713-4.
    View in: PubMed
    Score: 0.347
  10. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011 Feb; 32(1):102-10.
    View in: PubMed
    Score: 0.342
  11. Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys. 2011 Jan; 38(1):238-44.
    View in: PubMed
    Score: 0.335
  12. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009 Sep; 136(3):888-896.
    View in: PubMed
    Score: 0.306
  13. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008 Jun; 9(2-3):171-9.
    View in: PubMed
    Score: 0.285
  14. Current state and future directions of pleural mesothelioma imaging. Lung Cancer. 2008 Mar; 59(3):411-20.
    View in: PubMed
    Score: 0.271
  15. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005 Jun; 48(3):423-8.
    View in: PubMed
    Score: 0.223
  16. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.
    View in: PubMed
    Score: 0.202
  17. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma. J Thorac Oncol. 2023 12; 18(12):1689-1702.
    View in: PubMed
    Score: 0.201
  18. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000 Oct; 1(4):313-26.
    View in: PubMed
    Score: 0.165
  19. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999 Nov 15; 86(10):1985-91.
    View in: PubMed
    Score: 0.155
  20. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020 01; 15(1):29-49.
    View in: PubMed
    Score: 0.153
  21. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798.
    View in: PubMed
    Score: 0.151
  22. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019 04 01; 37(10):790-798.
    View in: PubMed
    Score: 0.147
  23. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. Eur Radiol. 2019 Jun; 29(6):2981-2988.
    View in: PubMed
    Score: 0.146
  24. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
    View in: PubMed
    Score: 0.144
  25. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019 Feb; 29(2):682-688.
    View in: PubMed
    Score: 0.141
  26. Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. World J Surg. 2018 04; 42(4):1036-1045.
    View in: PubMed
    Score: 0.139
  27. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
    View in: PubMed
    Score: 0.138
  28. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. Ann Thorac Surg. 2017 Mar; 103(3):962-966.
    View in: PubMed
    Score: 0.125
  29. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2112-2119.
    View in: PubMed
    Score: 0.125
  30. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2089-2099.
    View in: PubMed
    Score: 0.125
  31. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2100-2111.
    View in: PubMed
    Score: 0.125
  32. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
    View in: PubMed
    Score: 0.124
  33. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016 Oct; 102(4):1059-66.
    View in: PubMed
    Score: 0.124
  34. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016 Jun; 49(6):1642-7.
    View in: PubMed
    Score: 0.119
  35. Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. Ann Thorac Surg. 2015 Nov; 100(5):1868-74.
    View in: PubMed
    Score: 0.116
  36. Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2015 May; 99(5):1775-80.
    View in: PubMed
    Score: 0.112
  37. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36.
    View in: PubMed
    Score: 0.108
  38. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol. 2013 Apr; 8(4):478-86.
    View in: PubMed
    Score: 0.098
  39. Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013; 182-8.
    View in: PubMed
    Score: 0.096
  40. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005.
    View in: PubMed
    Score: 0.095
  41. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1728-34.
    View in: PubMed
    Score: 0.095
  42. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92.
    View in: PubMed
    Score: 0.094
  43. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9.
    View in: PubMed
    Score: 0.091
  44. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
    View in: PubMed
    Score: 0.090
  45. Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. Acad Radiol. 2011 Mar; 18(3):294-8.
    View in: PubMed
    Score: 0.084
  46. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
    View in: PubMed
    Score: 0.082
  47. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20; 27(18):3007-13.
    View in: PubMed
    Score: 0.074
  48. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
    View in: PubMed
    Score: 0.072
  49. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14.
    View in: PubMed
    Score: 0.071
  50. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008 Jul 20; 26(21):3567-72.
    View in: PubMed
    Score: 0.071
  51. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71.
    View in: PubMed
    Score: 0.069
  52. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
    View in: PubMed
    Score: 0.065
  53. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
    View in: PubMed
    Score: 0.059
  54. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005 Oct; 12(10):1301-9.
    View in: PubMed
    Score: 0.058
  55. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15; 11(6):2300-4.
    View in: PubMed
    Score: 0.056
  56. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004 May; 44(2):251-9.
    View in: PubMed
    Score: 0.053
  57. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004 May; 31(5):1105-15.
    View in: PubMed
    Score: 0.053
  58. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003 Apr 15; 21(8):1556-61.
    View in: PubMed
    Score: 0.049
  59. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.038
  60. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):9008-9013.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.